Reprint

Marine Natural Products and Obesity

Edited by
July 2019
194 pages
  • ISBN978-3-03921-191-3 (Paperback)
  • ISBN978-3-03921-192-0 (PDF)

This is a Reprint of the Special Issue Marine Natural Products and Obesity that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Obesity and related co-morbidities are increasing worldwide and pose a serious health problem. Changes in lifestyle and diet would be the best remedies to fight obesity; however, many people will still rely on medical aid. Marine organisms have been prolific in the production of bioactive compounds for many diseases, e.g., cancer, and promise to be an excellent source for natural-derived molecules and novel nutraceuticals. Bioactive compounds with beneficial activities towards obesity have been described from diverse marine organism including marine algae, bacteria, sponges, fungi, crustaceans or fish.

This Special Issue will highlight the progress in the following topics: Bioactive compounds for the treatment of obesity and obesity-related co-morbidities (diabetes, fatty liver, hyperlipidemia) from marine organisms; the isolation of novel compounds, the bioactivity screening of marine organisms and the elucidation of molecular mode of action of marine bioactive compounds.

Format
  • Paperback
License and Copyright
© 2019 by the authors; CC BY-NC-ND license
Keywords
3T3-L1 cells; fucan; lipolytic; obesity; brown seaweed; chitosan oligosaccharide; obesity; leptin; JAK2-STAT3; adipogenesis; collagen peptide; skate skin; high fat diet; fatty acid metabolism; cholesterol metabolism; chitosan oligosaccharide; glucolipid metabolism disorder; high-fat diet; inflammation; peroxisome proliferator-activated receptor gamma; cellularity; adipocyte; obesity; nutrition; fat; proliferation; white adipose tissue; adipogenesis; antiobesity; adipocytes; diphlorethohydroxycarmalol (DPHC); Skate skin; Raja kenojei; collagen; body fat; obesity; Ishige okamurae; marine alga; obesity; diabetes; nutraceuticals; zebrafish Nile red fat metabolism assay; anti-obesity drugs; chlorophyll derivatives; murine pre-adipocytes; PPARγ; Arthrospira maxima; dyslipidemia; physical exercise; obesity; double-blind; randomized controlled trial; anti-obesity drugs; metabolite profiling; zebrafish Nile red fat metabolism assay; uncoupling protein 1; bioactivity screening; diabetes; fatty liver disease; cyanobacteria; thermal proteome profiling; mechanisms of action; bioactive compound; label-free quantitative proteomics; marine biodiscovery; marine sponges; natural compounds; bisabolane-related compounds; bioactivity; obesity; whole small animal models